Project Grant R33CA302607
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $402K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This $204,027 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting the Weill Medical College of Cornell University in expanding single-cell and spatial technologies to link clonal genotypes with phenotypes during cancer evolution. The grant aims to develop advanced single-cell methods that can capture multiple data modalities, including genotypes, transcriptomes, methylomes, and protein expression, to better understand how somatic...
- This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...
- This federal Project Grant award, valued at $701,876.00, was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Weill Medical College of Cornell University. The award supports a systems-level approach to therapeutically targeting the STING protein in cancer. The project aims to develop a novel technology called SATseq that couples saturation mutagenesis with single-cell sequencing to map the structure-function landscape of the STING protein,...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This federal Project Grant award from the National Cancer Institute (NCI) under CFDA 93.396 (Cancer Biology Research) provides $182,755 to Cold Spring Harbor Laboratory (CSHL) to conduct research on genetic technology development for understanding lineage plasticity mechanisms in cancer. The award began on August 21, 2025 and is scheduled for completion on July 31, 2030. The key products and services to be delivered through this grant include: 1) developing a CRISPR screening methodology for...
- The U.S. National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant, with a period of performance from February 1, 2025 to January 31, 2027, will fund research to study the role of aberrant mRNA splicing in cancer cell heterogeneity and its potential as a target for immunotherapeutic strategies. The research aims to utilize advanced computational and single-cell approaches...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This Project Grant award for $450,904 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a single-cell (phospho-)proteomics platform at the Pacific Northwest National Laboratory, operated by Battelle Memorial Institute. The platform aims to address key challenges in single-cell proteomics analysis, including low recovery for phospho-enrichment, insufficient mass spectrometry sensitivity, and low sample throughput. This new platform will...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Weill Medical College of Cornell University to conduct research on the signal transduction mechanisms that regulate the activity of the p70 S6 kinase 1 (S6K1) protein. The primary objectives are to better understand how the mTOR complex 1 (mTORC1) signaling pathway regulates and coordinates cellular processes to promote cancer cell growth, proliferation, migration,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,006,599 to Weill Medical College of Cornell University from September 1, 2025 through August 31, 2029 to expand NCI-sponsored clinical research in hematologic malignancies to the Brooklyn and Queens regions of New York City. The funding supports the integration of interdisciplinary research at the Meyer Cancer Center to address cancer prevention, treatment, and educational outreach...